News and Trends 17 Oct 2018
Belgian Firm Will Develop Antibiotic Alternatives for Industrial Biotech Using CRISPR
Syngulon will be developing antibacterial peptides using CRISPR/Cas9 gene editing technology thanks to an agreement with ERS Genomics, which licenses out CRISPR intellectual property in the EU. CRISPR technology is a hot topic in the biotech industry because it makes gene editing faster and easier than other techniques. This could make it very useful in […]